Brokerages Set Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Target Price at $12.62

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) has earned an average rating of “Buy” from the nine research firms that are currently covering the stock, MarketBeat.com reports. Eight analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokers that have issued ratings on the stock in the last year is $12.6250.

Several analysts have issued reports on CATX shares. Royal Bank Of Canada reduced their price target on shares of Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating on the stock in a report on Tuesday, March 17th. B. Riley Financial upped their target price on shares of Perspective Therapeutics from $11.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, March 18th. BTIG Research reiterated a “buy” rating and set a $14.00 price target on shares of Perspective Therapeutics in a report on Tuesday, March 17th. Truist Financial set a $12.00 price objective on Perspective Therapeutics in a research report on Tuesday, March 17th. Finally, Wedbush reiterated an “outperform” rating and set a $11.00 target price on shares of Perspective Therapeutics in a research report on Tuesday, May 5th.

Perspective Therapeutics Stock Up 1.5%

Shares of CATX opened at $3.46 on Monday. Perspective Therapeutics has a twelve month low of $1.96 and a twelve month high of $6.16. The stock’s 50 day moving average is $3.60 and its two-hundred day moving average is $3.85.

Perspective Therapeutics (NYSEAMERICAN:CATX) last released its earnings results on Monday, May 11th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.04. The company had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.16 million. Perspective Therapeutics had a negative return on equity of 42.33% and a negative net margin of 17,982.69%. As a group, analysts anticipate that Perspective Therapeutics will post -1.11 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Perspective Therapeutics

A number of large investors have recently bought and sold shares of CATX. Seven Fleet Capital Management LP purchased a new stake in shares of Perspective Therapeutics during the 1st quarter valued at $1,581,000. Avidity Partners Management LP grew its position in Perspective Therapeutics by 88.4% during the first quarter. Avidity Partners Management LP now owns 6,049,999 shares of the company’s stock valued at $25,228,000 after acquiring an additional 2,839,266 shares during the period. Ally Bridge Group NY LLC purchased a new stake in Perspective Therapeutics during the first quarter valued at about $3,864,000. Yu Fan acquired a new stake in Perspective Therapeutics during the first quarter worth about $4,401,000. Finally, ADAR1 Capital Management LLC increased its stake in Perspective Therapeutics by 687.2% during the first quarter. ADAR1 Capital Management LLC now owns 749,335 shares of the company’s stock worth $3,125,000 after acquiring an additional 654,142 shares during the last quarter. Hedge funds and other institutional investors own 54.66% of the company’s stock.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.